Taku Kobayashi
@TakuKobayashiM1
Followers
1K
Following
1K
Media
72
Statuses
489
Gastroenterologist at Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. Account for English.
日本 東京
Joined September 2020
Dr. Charles Bernstein, distinguished professor of internal medicine @umanitoba's Max Rady College of Medicine, led the first global study on health-care spending for IBD, revealing critical gaps in diagnosis, treatment and access to care. @AGA_Gastro
news.umanitoba.ca
In the 1990s, Dr. Charles Bernstein, distinguished professor of internal medicine at the Rady Faculty of Health Sciences’ Max Rady College of Medicine, found that Canada had the highest rates of...
0
1
1
A true legend in the field of IBD - your memory will continue to inspire us Fitting tribute to Prof. Brian Feagan from #ECCO Family https://t.co/ogRVEAbW4t
ecco-ibd.eu
1
12
40
Gave four talks already and one more to go at JDDW in Kobe. Our study was well accepted and we learned a lot from our international speakers Prof Russel Cohen @UChicagoMed @PDulaiMD @sang_hyoung
0
2
17
I am honored to see our studies on transperineal ultrasound extensively presented by @Mathiar86 chaired by @DrSagami at ICIUS2025 in Brisbane. I am glad that I had an opportunity to mentor all these studies and am proud to see @DrSagami becoming a superstar!
0
1
25
An Early Phase 2 Double-Blind, Placebo-Controlled Study of E6011, a Novel Anti-Fractalkine Antibody, in Patients with Crohn’s Disease
karger.com
Abstract. Introduction: E6011 is a newly developed humanized monoclonal antibody that binds to and neutralizes fractalkine with high specificity and affinity. In a previous phase 1, open-label study,...
0
2
2
0
2
5
Mechanism of IL-10 production via IL-1R in gut macrophages https://t.co/X0ndr71hJG
0
0
0
Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study) https://t.co/Fj7kO8mNb6
1
1
5
Two hot weeks of @BowelUltrasound IBUS module 2 at Kitasato Institute Hospital successfully finished! Many, many thanks to @DrSagami who hosted and taught me, as well as @TakuKobayashiM1 who I became to respect more and more. And of course, thanks to my colleagues at #CAU for
0
2
19
Encountered several ASUC cases in which, despite showing a good initial response with reduced CRP to upadacitinib for several days, suddenly developed massive bleeding. We suspect that mucosal fragility due to IL-6 inhibition may be the cause. Any thoughts?
3
1
5
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis - Clinical Gastroenterology and Hepatology
cghjournal.org
Tofacitinib and upadacitinib are Janus kinase (JAK) inhibitors that are increasingly used for the treatment of acute severe ulcerative colitis (ASUC). However, comparative analyses of safety and...
1
21
36
Rinvoq Launch Symposium in Taipei. Congratulations to my friends, colleagues, and most importantly, to patients!
0
0
11
Our new data highlights the usefulness of transperineal ultrasound as an immediate treatment target for ulcerative colitis! Early Reduction in Rectal Wall Thickness on Transperineal Ultrasound Predicts Mucosal Healing in Ulcerative Colitis
academic.oup.com
AbstractBackground. Intestinal ultrasound (IUS) is a valuable tool for assessing short-term responses to treatment of ulcerative colitis (UC). Nevertheless
1
13
45
This multicenter study, led by UCLA, was published in @IBDJournals 👉Study of efficacy and safety of ustekinumab and vedolizumab for #Crohns disease of the pouch. 👥 @berkeleydoc Sunhee Park @Keyashian @eleanoryangmd @LauraMaasMD @alyssaparian et al https://t.co/TJFAbDaOsz
academic.oup.com
AbstractBackground and Aims. Medically refractory ulcerative colitis may require colectomy with ileal pouch-anal anastomosis. Complications of the J-pouch
0
3
22
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
academic.oup.com
AbstractBackground and aims. Concurrent achievement of symptomatic, endoscopic, and histologic remission, known as disease clearance, has been proposed as
0
0
7
Janus Kinase (JAK) Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study - Clinical Gastroenterology and Hepatology
cghjournal.org
JAK inhibitor–associated acne is a common but poorly understood adverse event. This study aimed to investigate the epidemiology, clinical characteristics, and treatment outcomes of this condition in...
0
12
18
I had the honor of playing the violin at the presidential dinner of AOCC 2025! I was more nervous than I’ve ever been—but I truly enjoyed the experience. Some people told me to change my job!? #aocc2025
5
7
53
Diagnosis and Management of Upper Gastrointestinal Involvement in Adul...
0
1
3
If you aren't willing to start advanced therapy in Crohn's disease in the first year, then maybe you should be referring new Crohn's disease diagnoses to an #IBD Center?
It's prime time to address barriers to advanced therapy. Despite their indication and availability, they are still underutilized. Studies have shown that the use of biologic therapy is related to improved outcomes (less bowel damage, therapy escalation, and surgery)
0
8
41
Time to EXIT? Our editorial on the EXIT study has been published.
0
0
3